Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

NCT07020832 ↗

Phase 3 Suspended 320 enrolled Apellis Pharmaceuticals, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Timeline

Start: 2026-05-18
Primary completion: 2029-06
Completion: 2030-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Pegcetacoplan	Peptide	20 ml	Intravenous

Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

Summary

Timeline

Drugs

Indications